Antitumoral Efficacy of Vitex negundo in Oral Cancer: An In vitro Study
Background: Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of all oral cancer cases. Cytotoxic chemotherapeutic drugs interfere with the replication and synthesis of DNA, promoting the death of cancer cells and normal cells as well. Researchers have extracted a number of bioactive substances including volatile oils, flavonoids, lignans, iridoids, and terpenes from the leaves, seeds, and roots of Vitex negundo. Anti-inflammatory, antioxidant, anticancer, and antibacterial properties are displayed by these bioactive substances. The present study proposed to establish the cytotoxic, apoptotic activity of crude ethanolic extract of Vitex negundo (VN) leaves on an oral cancer cell line.
Methods: The OSCC cell line was exposed to different concentrations of crude ethanolic extract of VN leaves and cisplatin for 24, 48, and 72 hours. The MTT assay was done to check for cell viability. IC50 was determined. The AO/PI assay for apoptosis was done at IC50 after 72 hours. Early and late apoptotic changes were observed in VN-treated and cisplatin-treated cells.
Results: In the human OSCC cell line, the percentage of viable cells decreased from 92.33 to 21.08 after 24 hours as the concentration increased from 20 µg/ml to 100 µg/ml. Cell viability decreased from 71.20% to 17.89% after 48 hours and from 61.40% to 14.75% after 72 hours. VN-treated cells were predominantly in the early stage of apoptosis with chromatin changes (yellow-green nucleus) as compared to cisplatin on AO/PI staining.
Conclusions: Crude ethanolic extract of VN leaves had similar cytotoxic and apoptotic efficacy to cisplatin on the OSCC cell line.
1. Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780-6.
2. Ali J, Sabiha B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral cancer. Oral Oncol. 2017;70:23-8.
3. Borse V, Konwar AN, Buragohain P. Oral cancer diagnosis and perspectives in India. Sens Int. 2020;1:100046.
4. Georgaki M, Theofilou VI, Pettas E, Stoufi E, Younis RH, Kolokotronis A. et al. Understanding the complex pathogenesis of oral cancer: A comprehensive review.
5. Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, et al. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023;15(1):44.
6. Padhi SS, Roy S, Kar M, Saha A, Roy S, Adhya A, et al. Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma. Oral Oncol. 2017;73:27-35.
7. Dhar H, Vaish R, D'Cruz AK. Management of locally advanced oral cancers. Oral Oncol. 2020;105:104662.
8. Nandini DB, Rao RS, Hosmani J, Khan S, Patil S, Awan KH. Novel therapies in the management of oral cancer: an update. Dis Mon. 2020;66(12):101036.
9. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367-1401.
10. Salmerón-Manzano E, Garrido-Cardenas JA, Manzano-Agugliaro F. Worldwide research trends on medicinal plants. Int J Environ Res Public Health. 2020;17(10):3376.
11. Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018;9:1300.
12. Lee TY, Tseng YH. The potential of phytochemicals in oral cancer prevention and therapy: a review of the evidence. Biomolecules. 2020;10(8):1150.
13. Gill BS, Mehra R, Navgeet, Kumar S. Vitex negundo and its medicinal value. Mol Biol Rep. 2018;45(6):2925-34.
14. Meena AK, Perumal A, Kumar N, Singh R, Ilavarasan R, Srikanth N, et al. Studies on physicochemical, phytochemicals, chromatographic profiling & estimation and in-silico study of Negundoside in roots & small branches of Vitex negundo plant. Phytomedicine Plus. 2022;2(1):100205.
15. Kadir FA, Kassim NM, Abdulla MA, Yehye WA. PASS-predicted Vitex negundo activity: antioxidant and antiproliferative properties on human hepatoma cells--an in vitro study. BMC Complement Altern Med. 2013;13:343.
16. Volpe DA, Hamed SS, Zhang LK. Use of different parameters and equations for calculation of IC50 values in efflux assays: potential sources of variability in IC50 determination. AAPS J. 2014;16(1):172-80.
17. Crimin KS, McKean JW, Vidmar TJ. Rank-based estimate of four-parameter logistic model. Pharm Stat. 2012;11(3):214-21.
18. He Y, Zhu Q, Chen M, Huang Q, Wang W, Li Q, et al. The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. Oncotarget. 2016;7(43):70803-21.
19. Liu K, Liu PC, Liu R, Wu X. Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res. 2015;21:15-20.
20. Atale N, Gupta S, Yadav UC, Rani V. Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. J Microsc. 2014;255(1):7-19.
21. Sun R, Dou W, Liu W, Li J, Han X, Li S, et al. Global, regional, and national burden of oral cancer and its attributable risk factors from 1990 to 2019. Cancer Med. 2023;12(12):13811-20.
22. Bosetti C, Carioli G, Santucci C, Bertuccio P, Gallus S, Garavello W, et al. Global trends in oral and pharyngeal cancer incidence and mortality. Int J Cancer. 2020;147(4):1040-9.
23. Saka-Herrán C, Jané-Salas E, Mari-Roig A, EstrugoDevesa A, López-López J. Time-to-treatment in oral cancer: causes and implications for survival. Cancers (Basel). 2021;13(6):1321.
24. van der Waal I. Are we able to reduce the mortality and morbidity of oral cancer; some considerations. Med Oral Patol Oral Cir Bucal. 2013;18(1):e33-7.
25. Geiger JL, Adelstein DJ. Chemotherapy in the definitive management of oral cancers: Where do we stand today? Oral Oncol. 2020;102:104584.
26. Sarma MK, Missong AK, Sharma M, Debnath A, Mahanta N, Choudhury MM. Comparison of post-operative complications in oral cancer treated with and without neoadjuvant chemotherapy. J Pharm Bioallied Sci. 2023;15(Suppl 2):S1116-8.
27. Zheng CJ, Li HQ, Ren SC, Xu CL, Rahman K, Qin LP, et al. Phytochemical and Pharmacological Profile of Vitex negundo. Phytother Res. 2015;29(5):633-47.
28. Rani A, Sharma A. The genus Vitex: A review. Pharmacogn Rev. 2013;7(14):188-98.
29. Kamal N, Mio Asni NS, Rozlan INA, Mohd Azmi MAH, Mazlan NW, Mediani A, et al. Traditional medicinal uses, phytochemistry, biological properties, and health applications of Vitex sp. Plants (Basel). 2022 ;11(15):1944.
30. Chan EWC, Wong SK, Chan HT. Casticin from Vitex species: a short review on its anticancer and anti-inflammatory properties. J Integr Med. 2018;16(3):147-152.
31. Ramchandani S, Naz I, Lee JH, Khan MR, Ahn KS. An overview of the potential antineoplastic effects of casticin. Molecules. 2020;25(6):1287.
32. Carbone K, Gervasi F, Kozhamzharova L, Altybaeva N, Sönmez Gürer E, Sharifi-Rad J, et al. Casticin as potential anticancer agent: recent advancements in multi-mechanistic approaches. Front Mol Biosci. 2023;10:1157558.
33. Xin H, Kong Y, Wang Y, Zhou Y, Zhu Y, Li D, et al. Lignans extracted from Vitex negundo possess cytotoxic activity by G2/M phase cell cycle arrest and apoptosis induction. Phytomedicine. 2013;20(7):640-7.
34. Vo GV, Nguyen TH, Nguyen TP, Do TH, Tran NM, Nguyen HT, et al. In silico and in vitro studies on the anti-cancer activity of artemetin, vitexicarpin and penduletin compounds from Vitex negundo. Saudi Pharm J. 2022;30(9):1301-14.
35. Awale S, Linn TZ, Li F, Tezuka Y, Myint A, Tomida A, et al. Identification of chrysoplenetin from Vitex negundo as a potential cytotoxic agent against PANC-1 and a panel of 39 human cancer cell lines (JFCR-39). Phytother Res. 2011;25(12):1770-5.
36. Chaudhry GE, Jan R, Naveed Zafar M, Mohammad H, Muhammad TST. Vitex rotundifolia fractions induced apoptosis in human breast cancer T-47D cell line via activation of extrinsic and intrinsic pathway. Asian Pac J Cancer Prev. 2019;20(12):3555-62.
37. Özlem Sultan Aslantürk, Tülay Aşkın Çelik. Antioxidant activity and anticancer effect of Vitex agnus-castus L. (Verbenaceae) seed extracts on MCF–7 breast cancer cells, Caryologia. 2013;66(3):257-67.
38. Ibrahim FM, Ibrahim AY, El-Newary SA, Hendawy SF, Mahomoodally MF. Vitex agnus-castus L.(Chasteberry) extracts shows in vitro and in vivo anti-inflammatory and anti-tumor propensities via reduction of cyclooxygenase-2 activity and oxidative stress complications. S Afr J Bot. 2021;143:363-73.
39. Ilhan S. Essential Oils from Vitex agnus castus L. Leaves induces caspase-dependent apoptosis of human multidrug-resistant lung carcinoma cells through intrinsic and extrinsic pathways. Nutr Cancer. 2021;73(4):694-702.
40. Gong G, Shen YL, Lan HY, Jin JM, An P, Zhang LJ, et al. The CYR61 is a potential target for rotundifuran, a natural labdane-type diterpene from vitex trifolia L., to trigger apoptosis of cervical cancer cells. Oxid Med Cell Longev. 2021;2021:6677687.
41. Mohammad MS, Shyam P. Bioactivity studies and Insilico studies of the isolated compound from ancient plant Vitex negundo against breast cancer. J Mol Struct. 2023;1288:135762.
42. Gouthami K, Veeraraghavan V, Nagaraja P. In-silico characterization of phytochemicals identified from Vitex negundo (L) extract as potential therapy for Wnt-signaling proteins. Egypt J Med Hum Genet. 2022;23:3.
43. Liu N, Wang KS, Qi M, Zhou YJ, Zeng GY, Tao J, et al. Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels. J Exp Clin Cancer Res. 2018;37(1):269.
44. Dehghani Nazhvani A, Sarafraz N, Askari F, Heidari F, Razmkhah M. Anti-cancer effects of traditional medicsinal herbs on oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2020;21(2):479-84.